Purple Biotech
PPBT
11 hedge funds and large institutions have $2.17M invested in Purple Biotech in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
2,155% more capital invested
Capital invested by funds: $96K → $2.17M (+$2.07M)
120% more funds holding
Funds holding: 5 → 11 (+6)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.12M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.21M |
| 3 |
Morgan Stanley
New York
|
+$300K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$292K |
| 5 |
Renaissance Technologies
New York
|
+$232K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $1.06M | +$2.12M | +1,731 | New |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $605K | +$1.21M | +989 | New |
|
|
3
Morgan Stanley
New York
| $171K | +$300K | +245 | +721% |
|
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $145K | +$292K | +238 | New |
|
|
5
Renaissance Technologies
New York
| $116K | +$232K | +189 | New |
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $47K | +$94.4K | +77 | New |
|
7
UBS Group
Zurich,
Switzerland
| $9K | +$13.5K | +11 | +275% |
|
|
KWM
8
Kingsview Wealth Management
Grants Pass,
Oregon
| $5K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| $5K | +$9.8K | +8 | New |
|
|
ASN
10
Advisory Services Network
Atlanta,
Georgia
| $3K | – | – | – |
|
|
RFA
11
Reilly Financial Advisors
La Mesa,
California
| $1K | +$1.23K | +1 | New |
|
PPBT Hedge Fund Activity: Q1 2020 in Review
11 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2020, worth a combined $2.17M — up 2,155% from $96K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPBT positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $2.12M.
- 11 institutional investors held Purple Biotech (PPBT) as of Q1 2020, up from 5 in Q4 2019.
- Funds reported $2.17M of Purple Biotech stock for Q1 2020, up 2,155% quarter-over-quarter.
- 7 funds opened new Purple Biotech positions in Q1 2020 and 0 closed out, a net change of +7 holders.
- The largest Purple Biotech buyer in Q1 2020 was OrbiMed, an estimated $2.12M added.
Based on aggregated 13F filings for Q1 2020.